首页> 外文学位 >In vitro diffusion studies for the assessment & optimization of promethazine hydrochloride dermatological formulations.
【24h】

In vitro diffusion studies for the assessment & optimization of promethazine hydrochloride dermatological formulations.

机译:体外扩散研究,用于评估和优化盐酸异丙嗪的皮肤病学制剂。

获取原文
获取原文并翻译 | 示例

摘要

Promethazine Hydrochloride, a phenothiazine derivative, has antihistamine (H1 receptor blocker) and anticholinergic properties. It is used clinically to prevent and control motion sickness, nausea, vomiting, and dizziness, to relieve or prevent allergic reactions, and to relax and sedate patients before and after surgery. Usually, promethazine is administered as a tablet and syrup and as a suppository. Topical and transdermal formulations. are not currently commercially available, however, sometimes, they are compounded by Pharmacists. This study was undertaken to develop and screen various topical formulations of promethazine with optimum release and permeation through the skin.;Various formulations containing 6.25%, 12.5% and 25% of drug were developed using cationic (Carbopol 934-P) gel base and nonionic (HPMCK100M) gel base. Also, the effects of penetration enhancers, dimethylsulfoxide (DMSO), lecithin and menthol at 5 and 10% levels were evaluated. In-vitro studies were performed with Franz Diffusion Cells using cellulose membrane and porcine ear skin as the diffusion barriers for 6 hours. The selected formulation with maximum drug release through cellulose membrane was then chosen for drug release through porcine ear skin.;Studies with cellulose membranes showed that release from cationic gel base release was superior to the nonionic gel base (Flux 0.07905 mg/cm 2hr and 0.01497 mg/cm2 hr respectively for 6.25% gel). The inclusion of additives at all levels had little or no effect in enhancing the drug release from these formulations. Among all the formulations tested, cationic gel base with 5% lecithin gave 2.6% drug release in 6 hour. The drug release of this formulation was then studied through porcine ear skin for 6 hours. Here, the drug release pattern remained similar to that observed with cellulose membrane, but the amount of total drug diffused was reduced as profiles. The Cationic gel base containing 5% lecithin with 12.5% of Promethazine hydrochloride gave the optimum release of drug. This study supports that with a proper composition of a dermatological vehicle, it is possible to develop a topical formulation with optimal drug release for a better clinical effect.
机译:盐酸异丙嗪是一种吩噻嗪衍生物,具有抗组胺药(H1受体阻滞剂)和抗胆碱能特性。它在临床上用于预防和控制晕动病,恶心,呕吐和头晕,缓解或预防过敏反应,以及在手术前后使患者放松和休息。通常,异丙嗪以片剂,糖浆剂和栓剂的形式给药。局部和透皮制剂。目前尚无市售药物,但是有时它们是由药剂师配制的。进行本研究的目的是开发和筛选具有最佳释放和透过皮肤渗透性的异丙嗪的各种局部制剂;使用阳离子(Carbopol 934-P)凝胶基质和非离子制剂开发了含有6.25%,12.5%和25%药物的各种制剂(HPMCK100M)凝胶基质。此外,还评估了渗透促进剂,二甲亚砜(DMSO),卵磷脂和薄荷醇在5%和10%含量下的作用。使用纤维素膜和猪耳皮肤作为扩散屏障,使用Franz Diffusion Cells进行了体外研究6小时。然后选择所选择的通过纤维素膜具有最大药物释放的制剂用于通过猪耳皮肤的药物释放;;具有纤维素膜的研究表明,从阳离子凝胶碱释放的释放优于非离子凝胶碱(通量0.07905 mg / cm 2hr和0.01497)分别为6.25%凝胶的mg / cm2小时)。在所有水平上包含添加剂对增强这些制剂的药物释放几乎没有影响。在所有测试的制剂中,具有5%卵磷脂的阳离子凝胶基质在6小时内释放了2.6%的药物。然后通过猪耳皮肤研究该制剂的药物释放6小时。在此,药物释放模式保持与纤维素膜上观察到的相似,但总药物扩散量减少了。包含5%卵磷脂和12.5%盐酸异丙嗪的阳离子凝胶基质可实现最佳的药物释放。这项研究支持采用适当的皮​​肤病学媒介物成分,可以开发出具有最佳药物释放效果的局部制剂,以取得更好的临床效果。

著录项

  • 作者

    Rana, Mayurkumar.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Pharmaceutical sciences.
  • 学位 M.S.
  • 年度 2014
  • 页码 115 p.
  • 总页数 115
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号